Company: TELO
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010298
Chunk: 26

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 2
Chunk 26
---
 2025

●
On January 7, 2025, we announced a preclinical progeria lifespan study conducted in collaboration with Nagi Bioscience SA. Utilizing
C. elegans (nematode) models, in which the study demonstrated restoration of shortened lifespan and normalization of accelerated aging
with Telomir-1.

●
On January 28, 2025, we announced that our studies demonstrated the ability of Telomir-1 to fully reverse copper-induced elevation of
ROS and provide robust cellular protection against copper toxicity.

●
On February 18, 2025, we announced that our studies had demonstrated the ability of Telomir-1 to significantly reverse copper and iron-induced
elevation of Reactive Oxygen Species (ROS).

●
On February 21, 2025, we announced that Telomir-1 had successfully captured and stabilized both Silver(I) (Ag⁺) and the highly
reactive Silver(II) (Ag²⁺) in a biologically compatible form.

●
On February 26, 2025, we announced that Telomir-1 fully reverses calcium dysregulation-an often-overlooked yet fundamental driver of
cell death, aging, and disease progression-in multiple human cell lines.

●
On March 19, 2025, we announced that Telomir-1 reduces tumor size by approximately 50% in a prostate cancer animal model using highly
aggressive human prostate cancer cells.

●
On May 7, 2025, we announced new preclinical data showing that our lead oral drug candidate, Telomir-1, reverses multiple hallmarks of
cellular decline across several human cell lines. The findings include improved mitochondrial activity, reduced oxidative stress, restored
calcium balance, and protection from toxic metal effects-offering a mechanistic foundation for our new research initiatives in autism
spectrum disorder (ASD) and spasmodic dysphonia (SD

14

Components
of Our Results of Operations

Research
and development expenses represent costs incurred to conduct research and development of our product candidate. We recognize all research
and development costs as they are incurred. Research and development expenses consist primarily of the following:

    ●
    contracted
    research and manufacturing;

    ●
    consulting
    arrangements; and

    ●
    other
    expenses incurred to advance the Company’s research and development activities.

Our
operating expenses have historically been the costs associated with